Firmonertinib
As of the edition of 20 October 2026, Firmonertinib is a small molecule: in active development; acts on EGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 70, 4 stopped early
- Disease areas
- Cancer; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EGFR | Epidermal growth factor receptor | P00533 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 2 | 4 | 1 |
| Phase 1 | 7 | 3 | 2 | 2 |
| Phase 2 | 45 | 2 | 31 | 1 |
| Phase 3 | 9 | 0 | 8 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 70 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Allist Pharmaceuticals | Lead sponsor of trials | 2016 to now |
| ArriVent BioPharma | Lead sponsor of trials | 2022 to now |
| InxMed | Lead sponsor of trials | 2023 to now |
| RemeGen | Lead sponsor of trials | 2023 to now |
| Jiangsu Alphamab Biopharmaceuticals | Lead sponsor of trials | 2025 to now |
| Minghui Pharmaceutical | Lead sponsor of trials | 2025 to now |